In 2017, the first report of a human TERT promoter-driven GAL4/upstream activating sequence (UAS) binding system for selective activation of CRISPR/Cas9 targeting the HRAS oncogene in bladder cancer cells was published [62]. This evidence concerns the gene HRAS and urinary bladder cancer.